Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B

Yao-Chun Hsu,Grace Lai-Hung Wong,Chien-Hung Chen,Cheng Yuan Peng,Ming-Lun Yeh,Ka-Shing Cheung,Hidenori Toyoda,Chung-Feng Huang,Huy N. Trinh,Qing Xie,Masaru Enomoto,Li Liu,Satoshi Yasuda,Yasuhito Tanaka,Ritsuzo Kozuka,Pei-Chien Tsai,Yen-Tsung Huang,Christopher Wong,Rui Huang,Tyng-Yuan Jang,Joseph Hoang,Hwai I. Yang,Jiayi Li,Dong Hyun Lee,Hirokazu Takahashi,Jian Q. Zhang,Eiichi Ogawa,Changqing Zhao,Chenghai Liu,Norihiro Furusyo,Yuichiro Eguchi,Clifford Wong,Chao Wu,Takashi Kumada,Man-Fung Yuen,Ming-Lung Yu,Mindie H. Nguyen

Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B

2019

INTRODUCTION:It is unclear whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) differ in their effectiveness for preventing hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB).METHODS:This retrospective cohort study analyzed an international consortium that encompas

Keywords:

Hepatitis B
Retrospective cohort study
General surgery
Hepatocellular carcinoma
Tenofovir
Medicine
Gastroenterology
Entecavir
Diabetes mellitus
Internal medicine
in patient
chronic hepatitis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations